Literature DB >> 31935280

High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity.

Tom Erkers1,2, Bryan J Xie1, Laura J Kenyon1,3, Brian Smith1, Mary Rieck4,5, Kent P Jensen6,7, Xuhuai Ji3, Marina Basina8, Samuel Strober6, Robert S Negrin1, Holden T Maecker3,9, Everett H Meyer1,7.   

Abstract

Human invariant natural killer T (iNKT) cells are a rare innate-like lymphocyte population that recognizes glycolipids presented on CD1d. Studies in mice have shown that these cells are heterogeneous and are capable of enacting diverse functions, and the composition of iNKT cell subsets can alter disease outcomes. In contrast, far less is known about how heterogeneity in human iNKT cells relates to disease. To address this, we used a high-dimensional, data-driven approach to devise a framework for parsing human iNKT heterogeneity. Our data revealed novel and previously described iNKT cell phenotypes with distinct functions. In particular, we found 2 phenotypes of interest: (1) a population with T helper 1 function that was increased with iNKT activation characterized by HLA-II+CD161- expression, and (2) a population with enhanced cytotoxic function characterized by CD4-CD94+ expression. These populations correlate with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation and with new onset type 1 diabetes, respectively. Our study identifies human iNKT cell phenotypes associated with human disease that could aid in the development of biomarkers or therapeutics targeting iNKT cells.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31935280      PMCID: PMC7068034          DOI: 10.1182/blood.2019001903

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets.

Authors:  Evan Z Macosko; Anindita Basu; Rahul Satija; James Nemesh; Karthik Shekhar; Melissa Goldman; Itay Tirosh; Allison R Bialas; Nolan Kamitaki; Emily M Martersteck; John J Trombetta; David A Weitz; Joshua R Sanes; Alex K Shalek; Aviv Regev; Steven A McCarroll
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

2.  Multiple immuno-regulatory defects in type-1 diabetes.

Authors:  Anjli Kukreja; Giulia Cost; John Marker; Chenhui Zhang; Zhong Sun; Karen Lin-Su; Svetlana Ten; Maureen Sanz; Mark Exley; Brian Wilson; Steven Porcelli; Noel Maclaren
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

3.  CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.

Authors:  Dominik Schneidawind; Antonio Pierini; Maite Alvarez; Yuqiong Pan; Jeanette Baker; Corina Buechele; Richard H Luong; Everett H Meyer; Robert S Negrin
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

4.  Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells.

Authors:  Jing Du; Katelyn Paz; Govindarajan Thangavelu; Dominik Schneidawind; Jeanette Baker; Ryan Flynn; Omar Duramad; Colby Feser; Angela Panoskaltsis-Mortari; Robert S Negrin; Bruce R Blazar
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

5.  Natural killer T cells in adipose tissue prevent insulin resistance.

Authors:  Henk S Schipper; Maryam Rakhshandehroo; Stan F J van de Graaf; Koen Venken; Arjen Koppen; Rinke Stienstra; Serge Prop; Jenny Meerding; Nicole Hamers; Gurdyal Besra; Louis Boon; Edward E S Nieuwenhuis; Dirk Elewaut; Berent Prakken; Sander Kersten; Marianne Boes; Eric Kalkhoven
Journal:  J Clin Invest       Date:  2012-08-06       Impact factor: 14.808

6.  Human CD4- invariant NKT lymphocytes regulate graft versus host disease.

Authors:  Tereza Coman; Julien Rossignol; Maud D'Aveni; Bettina Fabiani; Michael Dussiot; Rachel Rignault; Joel Babdor; Marie Bouillé; André Herbelin; Francine Coté; Ivan C Moura; Olivier Hermine; Marie-Thérèse Rubio
Journal:  Oncoimmunology       Date:  2018-08-23       Impact factor: 8.110

7.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome.

Authors:  Bo Li; Colin N Dewey
Journal:  BMC Bioinformatics       Date:  2011-08-04       Impact factor: 3.307

8.  Robust enumeration of cell subsets from tissue expression profiles.

Authors:  Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Methods       Date:  2015-03-30       Impact factor: 28.547

9.  Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain.

Authors:  S Porcelli; C E Yockey; M B Brenner; S P Balk
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

10.  Killer Cell Lectin-like Receptor G1 Inhibits NK Cell Function through Activation of Adenosine 5'-Monophosphate-Activated Protein Kinase.

Authors:  Bojana Müller-Durovic; Alessio Lanna; Luciana Polaco Covre; Rachel S Mills; Sian M Henson; Arne N Akbar
Journal:  J Immunol       Date:  2016-08-26       Impact factor: 5.422

View more
  3 in total

1.  Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects.

Authors:  Kristina Maas-Bauer; Juliane K Lohmeyer; Toshihito Hirai; Teresa Lopes Ramos; Furqan M Fazal; Ulrike M Litzenburger; Kathryn E Yost; Jessica V Ribado; Neeraja Kambham; Arielle S Wenokur; Po-Yu Lin; Maite Alvarez; Melissa Mavers; Jeanette Baker; Ami S Bhatt; Howard Y Chang; Federico Simonetta; Robert S Negrin
Journal:  Blood       Date:  2021-09-09       Impact factor: 25.476

Review 2.  Harnessing invariant natural killer T cells to control pathological inflammation.

Authors:  Nikhila S Bharadwaj; Jenny E Gumperz
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

Review 3.  iNKT: A new avenue for CAR-based cancer immunotherapy.

Authors:  Yilin Liu; Gang Wang; Dafei Chai; Yuanyuan Dang; Junnian Zheng; Huizhong Li
Journal:  Transl Oncol       Date:  2022-01-18       Impact factor: 4.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.